The 20 references in paper A. Chuchalin G., I. Tseymakh Ya., A. Momot P., A. Mamaev N., I. Karbyshev A., G. Kostyuchenko I., А. Чучалин Г., И. Цеймах Я., А. Момот П., А. Мамаев Н., И. Карбышев А., Г. Костюченко И. (2015) “Изменения системных воспалительных и гемостатических реакций у больных с обострением хронической обструктивной болезни легких с сопутствующими хронической сердечной недостаточностью и ожирением // Changes in systemic inflammatory and hemostatic response in patients with co-morbidity of exacerbation of chronic obstructive pulmonary disease, chronic heart failure and obesity” / spz:neicon:pulmonology:y:2014:i:6:p:25-32

1
Rabe K.F., Wedzicha J.A., Wouters E. F.M. et al. COPD and Comorbidity.Eur. Respir. Soc. Monograph.2013. DOI: 10.1183/1025448x.erm5913.
(check this in PDF content)
2
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2013 [electronic resource]. www.goldcopd.org.Available at: http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2013_ Feb20.pdf
(check this in PDF content)
3
Чучалин А.Г., ред. Хроническая обструктивная болезнь легких: Монография. М.: Атмосфера; 2008.
(check this in PDF content)
4
Авдеев С.Н. Хроническая обструктивная болезнь легких: обострения. Пульмонология. 2013; 3: 5–19.
(check this in PDF content)
5
Wakabayashi K., Gonzalez M., Delhaye C. Impact of Chronic Obstructive Pulmonary Disease on Acute-Phase Outcome of Myocardial Infarction. Am. J. Cardiol.2010; 106 (3): 305–309.
(check this in PDF content)
6
Singanayagam A., Schembri S., Chalmers J.D. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. A systematic review and meta-analysis.Ann. Am. Thorac. Soc. 2013; 10 (2): 81–89.
(check this in PDF content)
7
Cavaille`s A., Brinchault-Rabin G., Dixmier А. Comorbidities of COPD.Eur. Respir. Rev. 2013; 22: 454–475.
(check this in PDF content)
8
Gunen H., Gulbas G., In E. et al. Venous thromboemboli and exacerbations of COPD. Eur. Respir. J.2010; 35: 1243–1248.
(check this in PDF content)
9
Liu L., Miura K., Fujiyoshi A. et al. Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the United States and in Japan.Am. J. Cardiol.2014; 113 (1): 84–89.
(check this in PDF content)
10
Кузник Б.И. Клеточные и молекулярные механизмы регуляции системы гемостаза в норме и патологии. Чита:Экспресс-издательство; 2010.
(check this in PDF content)
11
Martin-Ventura J.L., Madrigal-Matute J., Martinez-Pinna R. et al. Erythrocytes, leukocytes and platelets as a source of oxidative stress in chronic vascular diseases: Detoxifying mechanisms and potential therapeutic options. Thromb. Haemost. 2012; 108: 435–442.
(check this in PDF content)
12
Högye M., Mándi Y., Csanády M. et al. Comparison of circulating levels of interleukin-6 and tumor necrosis factoralpha in hypertrophic cardiomyopathy and in idiopathic 30Пульмонология 6’2014 dilated cardiomyopathy. Am. J. Cardiol.2004; 94 (2): 249–251. 1. Rabe K.F., Wedzicha J.A., Wouters E.F.M. et al. COPD and Comorbidity. Eur. Respir. Soc. Monograph. 2013. DOI: 10.1183/1025448x.erm5913. 2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2013 [electronic resource]. www.goldcopd.org.Available at: http:// www.goldcopd.org/uploads/users/files/GOLD_Report_2013_ Feb20.pdf 3. Chuchalin A.
(check this in PDF content)
13
Zhengxun Z., Xincan L., Xiaoling C. et al. Relation of QRS duration and TNFA in patients with cardiac desynchronisation in chronic heart failure.Heart. 2011; 97 (Suppl. 3): А222.
(check this in PDF content)
14
National clinical guidelines of Russian Scientific Society of Cardiologists and Society of Heart Failure Specialists on Diagnosis and Treatment of Chronic Heart Failure (the 3rd revision approved by the SHFS Conference on the 15th, December, 2009). Heart Failure.2010; 11 (57): 3–62. Available at: http://www.scardio.ru/content/images/recommendation/Guidelines_SSHF_rev.3.01_2010.pdf (in Russian).
(check this in PDF content)
15
Barkagan Z.S., Momot A.P. Diagnosis and Supervised Therapy of Hemostasis Disorders. Moscow: N'yudiamed; 2008 (in Russian).
(check this in PDF content)
16
Momot A.P., ed. Recent Methods for Thrombotic Activity Detection. A Monograph. Barnaul: Izdatel'stvo Altayskogo universiteta; 2011 (in Russian).
(check this in PDF content)
17
Marcucci R., Gori A.M., Giannotti F. et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failure.J. Thromb. Haemost.2006; 4: 1017–1022.
(check this in PDF content)
18
Bendstrup K.E., Gram J., Jensen J.I. Effect of inhaled heparin on lung function and coagulation in healthy volunteers.Eur. Respir. J.2002; 19: 606–610.
(check this in PDF content)
19
Mannucci P.M., Bernardinelli L., Foco L. et al. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women.J. Thromb. Haemost. 2005; 3: 280–286.
(check this in PDF content)
20
Preissner K.T. Adipose tissue-derived PAI-1: A molecular link for thrombo-inflammatory disease states? J. Thromb. Haemost. 2012; 108: 485–492. Received September 22, 2014 UDC 6
(check this in PDF content)